LivaNova PLC (NASDAQ:LIVN) Sees Significant Decrease in Short Interest

LivaNova PLC (NASDAQ:LIVN) was the target of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 1,580,000 shares, a decrease of 18.6% from the February 13th total of 1,940,000 shares. Based on an average trading volume of 613,400 shares, the short-interest ratio is currently 2.6 days. Currently, 2.9% of the company’s stock are short sold.

Institutional Investors Weigh In On LivaNova

Several institutional investors and hedge funds have recently made changes to their positions in LIVN. Russell Investments Group Ltd. grew its stake in shares of LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after purchasing an additional 219 shares during the last quarter. Summit Investment Advisors Inc. lifted its holdings in LivaNova by 1.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock worth $780,000 after buying an additional 289 shares in the last quarter. Atria Investments Inc boosted its position in LivaNova by 6.2% in the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock valued at $297,000 after buying an additional 331 shares during the last quarter. Xponance Inc. increased its stake in shares of LivaNova by 6.1% in the 4th quarter. Xponance Inc. now owns 7,762 shares of the company’s stock valued at $359,000 after buying an additional 445 shares during the period. Finally, Mariner LLC increased its stake in shares of LivaNova by 8.4% in the 4th quarter. Mariner LLC now owns 5,741 shares of the company’s stock valued at $266,000 after buying an additional 446 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

LIVN has been the topic of a number of research analyst reports. Barclays lowered their target price on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research note on Friday, March 7th. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Mizuho dropped their price objective on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and set a $64.00 price target on shares of LivaNova in a report on Monday. Finally, Stifel Nicolaus lowered their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $61.17.

LivaNova Price Performance

Shares of LivaNova stock traded down $1.00 during trading on Tuesday, hitting $40.41. 642,560 shares of the company’s stock traded hands, compared to its average volume of 600,837. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market cap of $2.20 billion, a PE ratio of 96.21 and a beta of 1.10. LivaNova has a twelve month low of $36.85 and a twelve month high of $64.48. The firm’s fifty day moving average price is $45.88 and its 200 day moving average price is $49.01.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.